NASDAQ:LGND
Ligand Pharmaceuticals Incorporated Stock News
$86.06
+1.04 (+1.22%)
At Close: May 17, 2024
Outlook on the Worldwide Immune Checkpoint Inhibitors to 2022 - Featuring CureTech, NewLink Genetics & Novartis Among Others
08:08am, Wednesday, 01'st Apr 2020
Dublin, April 01, 2020 -- The "Global Immune Checkpoint Inhibitors Market Outlook 2022" report has been added to ResearchAndMarkets.com's offering. Given the.
XBI: Biotech ETF Expected To Outperform During And After The Coronavirus Pandemic
02:32pm, Tuesday, 31'st Mar 2020
S&P Biotech ETF (XBI) slumped -20% year-to-date, in-line with the S&P 500, due to the unrelenting coronavirus pandemic,. Heavy exposure to small caps contribute
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) Sees Significant Increase in Short Interest
05:54am, Tuesday, 31'st Mar 2020
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) was the target of a large increase in short interest in the month of March. As of March 13th, there was short interest totalling 8,904,900 shares, an increase
Oxford Asset Management LLP Invests $409,000 in Ligand Pharmaceuticals Inc. (NASDAQ:LGND)
11:10am, Monday, 30'th Mar 2020
Oxford Asset Management LLP bought a new position in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) during the 4th quarter, according to the company in its most recent Form 13F filing with the SE
Zacks: Analysts Anticipate Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to Post $0.61 Earnings Per Share
10:26am, Monday, 30'th Mar 2020
Equities analysts expect Ligand Pharmaceuticals Inc. (NASDAQ:LGND) to post earnings of $0.61 per share for the current fiscal quarter, Zacks reports. Two analysts have provided estimates for Ligand Ph
AQR Capital Management LLC Has $21.57 Million Holdings in Ligand Pharmaceuticals Inc. (NASDAQ:LGND)
09:14am, Friday, 27'th Mar 2020
AQR Capital Management LLC reduced its stake in shares of Ligand Pharmaceuticals Inc. (NASDAQ:LGND) by 20.9% in the 4th quarter, according to the company in its most recent 13F filing with the Securit
Ligand Pharmaceuticals (NASDAQ:LGND) Rating Lowered to Hold at BidaskClub
06:44am, Friday, 27'th Mar 2020
Ligand Pharmaceuticals (NASDAQ:LGND) was downgraded by stock analysts at BidaskClub from a “buy” rating to a “hold” rating in a research note issued to investors on Friday, BidAskClub reports.
Ligand Pharmaceuticals (NASDAQ:LGND) Trading 5.2% Higher
08:34am, Thursday, 26'th Mar 2020
Ligand Pharmaceuticals Inc. (NASDAQ:LGND) traded up 5.2% on Tuesday . The company traded as high as $76.20 and last traded at $74.18, 622,440 shares were traded during trading. An increase of 23% from
In Silico / Computer-Aided Drug Discovery Services Market: Focus on Large Molecules , 2020-2030
05:05pm, Tuesday, 24'th Mar 2020
INTRODUCTIONThe process of drug development, beginning from the discovery of a pharmacological lead to its commercial launch, is estimated to take around 10-15 years, involving capital investments in
Ligand downgraded to Hold from Buy at Argus LGND
12:23pm, Tuesday, 24'th Mar 2020
Ligand downgraded to Hold from Buy at Argus Argus LGND
Blair likes Incyte in premarket analyst action
11:53am, Tuesday, 24'th Mar 2020
Compugen (NASDAQ:CGEN) initiated with Buy rating and $16 (156% upside) price target at SunTrust. Shares up 9% premarket.Incyte (NASDAQ:INCY) resumed with Outperform rating at William Blair. Shares u
Ligand downgraded to Hold from Buy at Argus LGND
11:48am, Tuesday, 24'th Mar 2020
Ligand downgraded to Hold from Buy at Argus Argus LGND